Burning Rock Dx(US:BNR) Jin Rong Jie·2025-08-07 13:59Core Viewpoint - The stock price of Burning Stone Medical (BNR) increased by 22.95% on August 7, reaching $7.5 per share, with a total market capitalization of approximately $80.75 million [1]. Financial Performance - As of March 31, 2025, Burning Stone Medical reported total revenue of 133 million RMB, representing a year-on-year growth of 5.94% [1]. - The company recorded a net profit attributable to shareholders of -13.5 million RMB, showing a significant year-on-year improvement of 88.89% [1]. Upcoming Events - Burning Stone Medical is scheduled to disclose its mid-year report for the fiscal year 2025 on August 28, with the actual disclosure date subject to company announcements [1]. Company Background - Founded in 2014, Burning Stone Medical focuses on providing clinically valuable next-generation sequencing (NGS) for precision oncology, with a mission to "guard the light of life with science" [1]. - The company's business and research directions include: 1) detection of cancer patient populations, holding a leading market share in China; 2) collaboration with global anti-cancer pharmaceutical companies on biomarkers and companion diagnostics; 3) early detection of multiple cancer types [1]. Regulatory Milestones - In July 2018, Burning Stone Medical received the first certification for NGS testing kits for tumors from the National Medical Products Administration (NMPA) in China, marking a milestone in the field of in vitro diagnostics [2]. - The laboratory located in Guangzhou has passed the technical review by the Guangdong Provincial Clinical Testing Center and has obtained quality system certifications from CLIA and CAP in the United States [2]. - The laboratory in California has also received CLIA and CAP certifications, indicating the company's commitment to developing innovative and reliable NGS testing products [2].